Total Payments
$372,369
2024 Payments
$34,125
Companies
62
Transactions
1,347
Medicare Patients
1,532
Medicare Billing
$1.8M
Payment Breakdown by Category
Other$252,082 (67.7%)
Consulting$72,245 (19.4%)
Food & Beverage$22,705 (6.1%)
Travel$20,821 (5.6%)
Gifts$2,859 (0.8%)
Research$1,477 (0.4%)
Education$180.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $248,482 | 125 | 66.7% |
| Consulting Fee | $72,245 | 33 | 19.4% |
| Food and Beverage | $22,705 | 1,129 | 6.1% |
| Travel and Lodging | $20,821 | 47 | 5.6% |
| Honoraria | $3,600 | 2 | 1.0% |
| Gift | $2,859 | 4 | 0.8% |
| Unspecified | $1,477 | 2 | 0.4% |
| Education | $180.59 | 5 | 0.0% |
Payments by Type
General
$370,892
1,345 transactions
Research
$1,477
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $112,559 | 219 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $74,644 | 94 | $0 (2024) |
| EMD Serono, Inc. | $41,304 | 88 | $0 (2024) |
| Genentech USA, Inc. | $33,671 | 85 | $0 (2024) |
| GENZYME CORPORATION | $26,344 | 50 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $25,663 | 86 | $0 (2023) |
| Celgene Corporation | $18,214 | 47 | $0 (2024) |
| TG Therapeutics, Inc. | $14,166 | 32 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $6,302 | 11 | $0 (2019) |
| Horizon Therapeutics plc | $5,487 | 39 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,125 | 195 | Alexion Pharmaceuticals, Inc. ($14,045) |
| 2023 | $15,896 | 175 | Alexion Pharmaceuticals, Inc. ($7,681) |
| 2022 | $11,191 | 105 | Alexion Pharmaceuticals, Inc. ($5,190) |
| 2021 | $6,132 | 88 | Alexion Pharmaceuticals, Inc. ($4,215) |
| 2020 | $36,147 | 77 | Biogen, Inc. ($22,627) |
| 2019 | $107,224 | 224 | Alexion Pharmaceuticals, Inc. ($39,124) |
| 2018 | $65,943 | 219 | Biogen, Inc. ($28,786) |
| 2017 | $95,709 | 264 | Biogen, Inc. ($38,726) |
All Payment Transactions
1,347 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: IMMUNOLOGY | ||||||
| 12/23/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: Neurology | ||||||
| 12/18/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: Neurology | ||||||
| 12/17/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $30.71 | General |
| Category: Neuropsychiatry | ||||||
| 12/11/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $100.19 | General |
| 12/11/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $11.74 | General |
| Category: PAIN | ||||||
| 12/05/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $10.41 | General |
| Category: Neurology | ||||||
| 12/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: Neuropsychiatry | ||||||
| 11/26/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,712.50 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
| 11/19/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Neuropsychiatry | ||||||
| 11/18/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/11/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $116.66 | General |
| Category: Neuroscience | ||||||
| 11/06/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $29.63 | General |
| Category: Rare Disease | ||||||
| 11/04/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $32.69 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| COMB157GUS12 | Novartis Pharmaceuticals Corporation | $1,477 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 226 | 769 | $152,759 | $25,157 |
| 2022 | 9 | 323 | 14,873 | $2.4M | $612,406 |
| 2021 | 9 | 353 | 12,398 | $2.0M | $493,063 |
| 2020 | 14 | 630 | 16,239 | $2.7M | $641,492 |
Total Patients
1,532
Total Services
44,279
Medicare Billing
$1.8M
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 149 | 252 | $88,509 | $15,888 | 18.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 20 | 134 | $32,430 | $5,019 | 15.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 15 | 33 | $19,800 | $2,252 | 11.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 18 | 279 | $5,580 | $1,070 | 19.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 26 | $3,380 | $476.58 | 14.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 13 | 45 | $3,060 | $451.70 | 14.8% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2022 | 15 | 13,800 | $2.2M | $572,356 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 149 | 263 | $54,441 | $20,605 | 37.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 21 | 156 | $38,220 | $7,397 | 19.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 18 | 43 | $25,800 | $3,509 | 13.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 46 | 54 | $9,450 | $2,692 | 28.5% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 23 | 400 | $8,000 | $1,790 | 22.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,396 | $1,671 | 38.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 16 | 78 | $10,140 | $1,632 | 16.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 21 | 65 | $4,420 | $754.26 | 17.1% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2021 | 14 | 11,400 | $1.9M | $455,289 | 24.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 120 | 177 | $38,683 | $13,164 | 34.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 116 | 147 | $18,090 | $7,881 | 43.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 17 | 135 | $28,350 | $7,007 | 24.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 19 | 55 | $33,000 | $4,710 | 14.3% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 15 | 69 | $8,970 | $1,581 | 17.6% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2021 | 22 | 356 | $7,120 | $1,524 | 21.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $3,286 | $1,320 | 40.2% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 18 | 47 | $3,196 | $586.09 | 18.3% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2020 | 15 | 13,800 | $2.2M | $579,361 | 25.8% |
About Dr. Emily Riser, MD
Dr. Emily Riser, MD is a Specialist healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124115068.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emily Riser, MD has received a total of $372,369 in payments from pharmaceutical and medical device companies, with $34,125 received in 2024. These payments were reported across 1,347 transactions from 62 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($248,482).
As a Medicare-enrolled provider, Riser has provided services to 1,532 Medicare beneficiaries, totaling 44,279 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Birmingham, AL
- Active Since 10/10/2006
- Last Updated 04/16/2009
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1124115068
Products in Payments
- TECFIDERA (Drug) $36,820
- TYSABRI (Biological) $32,387
- AUBAGIO (Drug) $26,099
- COPAXONE (Drug) $25,407
- OCREVUS (Biological) $24,051
- ZINBRYTA (Biological) $18,743
- Mavenclad (Biological) $17,328
- BRIUMVI (Drug) $14,166
- Rebif (Biological) $13,084
- Ozanimod (Drug) $11,577
- Non-Covered Product (Drug) $9,227
- SOLIRIS (Biological) $8,675
- ACTHAR (Biological) $6,743
- ZEPOSIA (Drug) $6,662
- Soliris (Drug) $6,504
- Mavenclad (Drug) $6,001
- UPLIZNA (Drug) $5,487
- VUMERITY (Drug) $3,637
- ULTOMIRIS (Biological) $3,504
- GILENYA (Drug) $2,907
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Birmingham
Dr. Weily Soong, M.d, M.D
Specialist — Payments: $920,269
Specialist $920,269
Dr. Pamela Mclain, M.d, M.D
Specialist — Payments: $340,290
Specialist $340,290
Dr. Michael Sillers, Md, MD
Specialist — Payments: $286,019
Specialist $286,019
Jason Thompson, M.d, M.D
Specialist — Payments: $228,177
Specialist $228,177
Dr. Stanley Hewlett, Md, MD
Specialist — Payments: $116,582
Specialist $116,582
Dr. John Riser, Md, MD
Specialist — Payments: $41,767
Specialist $41,767